Brief: HLS Therapeutics Inc Reports Q3 Net Loss $0.05 Per Common Share
05/11/2020 12:39
Nov 5 (Reuters) - HLS Therapeutics Inc HLS.TO :
* HLS THERAPEUTICS ANNOUNCES Q3 2020 FINANCIAL RESULTS AND
NORMAL
COURSE ISSUER BID
* HLS THERAPEUTICS INC - QTRLY NET LOSS WAS $0.05 PER COMMON
SHARE
* HLS THERAPEUTICS INC - QTRLY REVENUE $13.1 MILLION VERSUS
$13.4
MILLION
* HLS THERAPEUTICS INC - NORMAL COURSE ISSUER BID BECOMES
EFFECTIVE NOVEMBER 9, 2020
Source text for Eikon: ID:nCNWF6tbga
Further company coverage: HLS.TO
Recent news on HLS Therapeutics
See all newsCanada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group
Canada's HLS Therapeutics Q1 revenue rises on Vascepa growth, reaffirms 2026 guidance
Canada's HLS Therapeutics Q4 revenue slightly beats on Vascepa strength
Brief: Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease
Brief: HLS Therapeutics announces Health Canada approval of NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease